Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| 36.33 | |
| 38.4 | |
| - | |
| 39.185 | |
| 33.98 | |
| 9.15-97.91 | |
| 358 M | |
| 9 299 K | |
| 0 | |
| -2.4287 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo No...
Biotech veteran brings more than two decades of life science experience to Korro’s Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceu...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
